|Dev R1*, Delgado-Guay MO1, De La Cruz M1, Rhondali W2, Hui D1 and Bruera E1|
|1Department of Palliative Care and Rehabilitation Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA|
|2Centre Hospitalier de Lyon Sud, Hospices Civils de Lyon, Lyon, France|
|Corresponding Author :||Rony Dev DO
Department of Palliative Care and Rehabilitation Medicine
Unit 1414, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
|Received June 19, 2014; Accepted August 26, 2014; Published September 06, 2014|
|Citation: Dev R, Delgado-Guay MO, De La Cruz M, Rhondali W, Hui D, et al. (2014) Feasibility of a Randomized Controlled Trial of Light Therapy in Cancer Patients with Insomnia. J Palliat Care Med 4:183. doi:10.4172/2165-7386.1000183|
|Copyright: © 2014 Dev R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Visit for more related articles at Journal of Palliative Care & Medicine
Purpose: The primary objective of our study was to compare bright light therapy versus dim red light for global
sleep quality in palliative care patients with cancer.
Methods: The study was designed as a randomized, double blind, placebo controlled trial. Patients initiated
blinded phase, either daily bright light versus red light placebo, from day 1 to day 14, then proceeded to an open
label phase between day 15 to day 28.
Results: Of the 319 outpatients assessed for eligibility, 97 patients (30%) fulfilled criteria for the study. Of the 97
patients, only 12 patients (12%) enrolled in the study with the majority unwilling to participate or reported a lack of
interest in light therapy. Only 4 patients (33%) completed the trial to the primary endpoint at 2 weeks.
Conclusion: At our institution, a randomized controlled trial examining bright light therapy, a potentially safe and
effective non-pharmacological approach to treat sleep disturbances, was not feasible for palliative care patients with
cancer. Future studies should be tailored to advanced cancer patients who are often frail and have a high symptom
burden, incorporate alternative trial designs such as randomization without a placebo arm, and consider integration
of home visits or assessment by phone calls to lessen the burden of participation in a clinical trial.